DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15

About this update from Dogwood Therapeutics, Inc.

[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:DWTX","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL DWTX RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Positive Interim Results for Phase 2b Trial of Halneuron® in CINP","length":65,"tagName":"p"},{"type":"text","content":"On December 22, 2025, Dogwood Therapeutics, Inc. (DWTX) announced positive interim results for the Phase 2b HALT-CINP (Halneuron® Treatment of Chemotherapy-Induced Neuropathic Pain) trial. Unblinded data from the trial was reviewed by the independent statistical review committee and concluded that Halneuron-treated patients are demonstrating separation from placebo-treated patients in pain improvement over the four-week study. The interim analysis included data from 97 patients that have completed treatment.","length":513,"tagName":"p"},{"type":"text","content":"Based on the current pace of enrollment and the interim assessment results, we anticipate topline results from the trial in the third quarter of 2026. The trial is currently 80-85% powered to detect a Halneuron treatment difference based on current patient enrollment trends.","length":275,"tagName":"p"},{"type":"text","content":"The Phase 2b trial is a four-week study that is examining the safety and efficacy of Halneuron in patients with moderate-to-severe CINP. The primary efficacy endpoint is the change from baseline at Week 4 in the weekly average of daily 24-hour recall pain intensity scores, which will be recorded in e-diary’s on participants smartphones. Secondary efficacy endpoints include Patient Global Impression of Change (PIGC), PROMIS Fatigue, PROMIS Sleep, PROMIS-29, Pain Interference, Hospital Anxiety and Depression Scale (HADS), and Neuropathic Pain Symptom Inventory (NPSI).","length":572,"tagName":"p"},{"type":"text","content":"Background on Halneuron","length":23,"tagName":"p"},{"type":"text","content":"Halneuron (tetrodotoxin, TTX), a sodium channel blocker, was originally discovered in the pufferfish and subsequent research has identified the toxin in 13 phyla (in both Eukarya and Bacteria) that includes both marine and terrestrial eukaryotes (Lago et al., 2015). As a natural poison, TTX is extremely effective and is the most potent non-pep...

More updates from Dogwood Therapeutics, Inc.